

Pfizer CEO: ‘Every Year You Will Have to Get Your Annual Shot for COVID’

Pfizer said this week it’s begun testing a third dose of its COVID vaccine and a new modified version to address variants for years to come.

By [Megan Redshaw](#)

Global Research, March 01, 2021

[Children's Health Defense](#) 26 February 2021

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles **can be read in 27 languages by activating the “Translate Website”** drop down menu on the top banner of our home page (Desktop version).

*Despite the [purported](#) 95% effectiveness of the [Pfizer-BioNTech](#) COVID-19 vaccine, Pfizer CEO **Albert Bourla** [announced](#) Thursday that the vaccine maker is testing a third dose of its vaccine in anticipation of annual booster shots.*

In a [press release](#), Pfizer stated its goal was to understand the effect of a booster on immunity against COVID caused by the circulating and newly emerging [SARS-CoV-2](#) variants and to engage in ongoing discussions with the U.S Food and Drug Administration (FDA) and European Medicines Agency regarding a clinical trial to test a modified [mRNA vaccine](#).

Pfizer director and board member **Scott Gottlieb**, who also served as [former FDA commissioner](#) in charge of vaccine approval, [told](#) CNBC the vaccine maker is exploring two paths to boost effectiveness of the COVID vaccine.

The first study will give 144 participants from the phase 1 clinical trial conducted last May a third lower-dosage of the current two-dose formulation. The second study involves testing a modified version of the existing vaccine designed to provide broad defense against a range of [COVID](#) mutations.

Pfizer hopes to prepare for a potential rapid adoption of the vaccine to address new variants that will allow for the development of booster vaccines within weeks. This “regulatory pathway” is already established for other infectious diseases like influenza, [said](#) the vaccine maker.

Pfizer’s CEO hopes a third dose will boost the immune response even higher or will offer protection against COVID variants.

“Every year, you need to go to get your [flu vaccine](#),” Bourla said. “It’s going to be the same with COVID. In a year, you will have to go and get your annual shot for Covid to be protected,” Bourla [told](#) NBC News.

The Pfizer-BioNTech COVID vaccine is not yet licensed by the FDA but has obtained [Emergency Use Authorization](#) (EUA) to prevent COVID-19 for use in ages 16 years and older. The emergency use of this vaccine is only authorized as long as “circumstances exist justifying the authorization of emergency use.”

The FDA has [said](#) it is willing to authorize [booster shots](#) based on small clinical trials, accepting data on how well vaccines prime the immune system rather than holding out for [long-term](#) safety and efficacy results on protecting against COVID-19.

Moderna is also [bolstering](#) its worldwide manufacturing capacity in anticipation of a sustained demand for COVID-19 boosters in the coming years. The company plans to test additional doses of their vaccine, booster shots and a new shot combined with its current vaccine as soon as regulators give the green light.

As [The Defender reported](#) last week, **Bill Gates** is also on record suggesting a “third shot” could be required to combat COVID.

*

Note to readers: please click the share buttons above or below. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

***Megan Redshaw** is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.*

Featured image is from Children's Health Defense

The original source of this article is [Children's Health Defense](#)
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca